메뉴 건너뛰기




Volumn 28, Issue 6, 2010, Pages 617-623

Methotrexate, paclitaxel, ifosfamide, and cisplatin in poor-risk nonseminomatous germ cell tumors

Author keywords

Cisplatin; Germ cell tumor; Ifosfamide; Methotrexate; Paclitaxel; Poor risk

Indexed keywords

ANTIBIOTIC AGENT; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; ERYTHROPOIETIN; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA; METHOTREXATE; PACLITAXEL; RANITIDINE;

EID: 78149383925     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2008.10.013     Document Type: Article
Times cited : (7)

References (40)
  • 1
    • 4644330119 scopus 로고    scopus 로고
    • European consensus on diagnosis and treatment of germ cell cancer: A report of the European Germ Cell Cancer Consensus Group (EGCCCG)
    • European Germ Cell Cancer Consensus Group
    • Schmoll H.J., Souchon R., Krege S., et al. European consensus on diagnosis and treatment of germ cell cancer: A report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004, 15:1377-1399. European Germ Cell Cancer Consensus Group.
    • (2004) Ann Oncol , vol.15 , pp. 1377-1399
    • Schmoll, H.J.1    Souchon, R.2    Krege, S.3
  • 2
    • 0030857028 scopus 로고    scopus 로고
    • Testicular germ-cell cancer
    • Bosl G.J., Motzer R.J. Testicular germ-cell cancer. N Engl J Med 1997, 337:242-253.
    • (1997) N Engl J Med , vol.337 , pp. 242-253
    • Bosl, G.J.1    Motzer, R.J.2
  • 3
    • 0031037241 scopus 로고    scopus 로고
    • International germ cell consensus classification: A prognostic factor-based staging system for metastatic germ cell cancers
    • International Germ Cell Cancer Collaborative Group
    • International germ cell consensus classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997, 15:594-603. International Germ Cell Cancer Collaborative Group.
    • (1997) J Clin Oncol , vol.15 , pp. 594-603
  • 4
    • 0025875021 scopus 로고
    • Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: A Southeastern Cancer Study Group and Southwest Oncology Group protocol
    • Nichols C.R., Williams S.D., Loehrer P.J., et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: A Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 1991, 9:1163-1172.
    • (1991) J Clin Oncol , vol.9 , pp. 1163-1172
    • Nichols, C.R.1    Williams, S.D.2    Loehrer, P.J.3
  • 5
    • 0344806946 scopus 로고    scopus 로고
    • Cisplatin, etoposide, and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: Final analysis of an intergroup trial
    • Hinton S., Catalano P.J., Einhorn L.H., et al. Cisplatin, etoposide, and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: Final analysis of an intergroup trial. Cancer 2003, 97:1869-1875.
    • (2003) Cancer , vol.97 , pp. 1869-1875
    • Hinton, S.1    Catalano, P.J.2    Einhorn, L.H.3
  • 6
    • 33846259793 scopus 로고    scopus 로고
    • Genito-Urinary Group of the French Federation of Cancer Centers (GETUG). Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumors: Mature results of a randomized trial
    • Droz J.P., Kramar A., Biron P., et al. Genito-Urinary Group of the French Federation of Cancer Centers (GETUG). Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumors: Mature results of a randomized trial. Eur Urol 2007, 51:739-746.
    • (2007) Eur Urol , vol.51 , pp. 739-746
    • Droz, J.P.1    Kramar, A.2    Biron, P.3
  • 7
    • 33846917709 scopus 로고    scopus 로고
    • Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors
    • Motzer R.J., Nichols C.J., Margolin K.A., et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 2007, 25:247-256.
    • (2007) J Clin Oncol , vol.25 , pp. 247-256
    • Motzer, R.J.1    Nichols, C.J.2    Margolin, K.A.3
  • 8
    • 0027996483 scopus 로고
    • Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors
    • Motzer R.J., Bajorin D.F., Schwartz L.H., et al. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 1994, 12:2277-2283.
    • (1994) J Clin Oncol , vol.12 , pp. 2277-2283
    • Motzer, R.J.1    Bajorin, D.F.2    Schwartz, L.H.3
  • 9
    • 0030052587 scopus 로고    scopus 로고
    • Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer
    • Bokemeyer C., Beyer J., Metzner B., et al. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 1996, 7:31-34.
    • (1996) Ann Oncol , vol.7 , pp. 31-34
    • Bokemeyer, C.1    Beyer, J.2    Metzner, B.3
  • 10
    • 0032055188 scopus 로고    scopus 로고
    • A phase II trial of paclitaxel in refractory germ cell tumors
    • Sandler A.B., Cristou A., Fox S., et al. A phase II trial of paclitaxel in refractory germ cell tumors. Cancer 1998, 82:1381-1386.
    • (1998) Cancer , vol.82 , pp. 1381-1386
    • Sandler, A.B.1    Cristou, A.2    Fox, S.3
  • 11
    • 0028153260 scopus 로고
    • Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design
    • Chou T.C., Motzer R.J., Tong Y., et al. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design. J Natl Cancer Inst 1994, 86:1517-1524.
    • (1994) J Natl Cancer Inst , vol.86 , pp. 1517-1524
    • Chou, T.C.1    Motzer, R.J.2    Tong, Y.3
  • 12
    • 0033976336 scopus 로고    scopus 로고
    • Ifosfamide-based drug combinations: Preclinical evaluation of drug interactions and translation into the clinic
    • Vanhoefer U., Schleucher N., Klaassen U., et al. Ifosfamide-based drug combinations: Preclinical evaluation of drug interactions and translation into the clinic. Semin Oncol 2000, 27(1 Suppl 1):8-13.
    • (2000) Semin Oncol , vol.27 , Issue.1 SUPPL. 1 , pp. 8-13
    • Vanhoefer, U.1    Schleucher, N.2    Klaassen, U.3
  • 13
    • 0034126766 scopus 로고    scopus 로고
    • Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer
    • Motzer R.J., Sheinfeld J., Mazumdar M., et al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 2000, 18:2413-2418.
    • (2000) J Clin Oncol , vol.18 , pp. 2413-2418
    • Motzer, R.J.1    Sheinfeld, J.2    Mazumdar, M.3
  • 14
    • 27244441799 scopus 로고    scopus 로고
    • Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors
    • Kondagunta G.V., Bacik J., Donadio A., et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 2005, 23:6549-6555.
    • (2005) J Clin Oncol , vol.23 , pp. 6549-6555
    • Kondagunta, G.V.1    Bacik, J.2    Donadio, A.3
  • 15
    • 14744287998 scopus 로고    scopus 로고
    • In vitro chemosensitivity test for human genito-urinary tumors using collagen gel matrix
    • Koshida K., Egawa M., Imao T., et al. In vitro chemosensitivity test for human genito-urinary tumors using collagen gel matrix. Int J Urol 2005, 12:67-72.
    • (2005) Int J Urol , vol.12 , pp. 67-72
    • Koshida, K.1    Egawa, M.2    Imao, T.3
  • 16
    • 0023739339 scopus 로고
    • Single agent activity of methotrexate in advanced non-seminomatous testicular germ cell tumors
    • Smith D.B., Rustin G.J., Hitchins R., et al. Single agent activity of methotrexate in advanced non-seminomatous testicular germ cell tumors. Eur J Cancer Clin Oncol 1988, 24:1779-1781.
    • (1988) Eur J Cancer Clin Oncol , vol.24 , pp. 1779-1781
    • Smith, D.B.1    Rustin, G.J.2    Hitchins, R.3
  • 17
    • 0014142575 scopus 로고
    • A chemotherapeutic approach to advanced testicular carcinoma
    • Wyatt J.K., McAninch L.N. A chemotherapeutic approach to advanced testicular carcinoma. Can J Surg 1967, 10:421-426.
    • (1967) Can J Surg , vol.10 , pp. 421-426
    • Wyatt, J.K.1    McAninch, L.N.2
  • 18
    • 0015326129 scopus 로고
    • Chemotherapy for metastatic teratomas of the testis
    • Smithers D.W. Chemotherapy for metastatic teratomas of the testis. Br J Urol 1972, 44:217-228.
    • (1972) Br J Urol , vol.44 , pp. 217-228
    • Smithers, D.W.1
  • 19
    • 0031926303 scopus 로고    scopus 로고
    • New prospects for the treatment of germ-cell tumors
    • Droz J.P., Culine S. New prospects for the treatment of germ-cell tumors. Expert Opin Investig Drugs 1998, 7:1139-1157.
    • (1998) Expert Opin Investig Drugs , vol.7 , pp. 1139-1157
    • Droz, J.P.1    Culine, S.2
  • 20
    • 0032797317 scopus 로고    scopus 로고
    • Sixty percent salvage rate for germ-cell tumors using sequential m-BOP, surgery, and ifosfamide-based chemotherapy
    • Shamash J., Oliver R.T., Ong J., et al. Sixty percent salvage rate for germ-cell tumors using sequential m-BOP, surgery, and ifosfamide-based chemotherapy. Ann Oncol 1999, 10:685-692.
    • (1999) Ann Oncol , vol.10 , pp. 685-692
    • Shamash, J.1    Oliver, R.T.2    Ong, J.3
  • 21
    • 0344417927 scopus 로고    scopus 로고
    • BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: The Spanish Germ-Cell Cancer Group experience (GG)
    • Germà-Lluch J.R., Garcia del Muro X., Tabernero J.M., et al. BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: The Spanish Germ-Cell Cancer Group experience (GG). Ann Oncol 1999, 10:289-293.
    • (1999) Ann Oncol , vol.10 , pp. 289-293
    • Germà-Lluch, J.R.1    Garcia del Muro, X.2    Tabernero, J.M.3
  • 22
    • 18444394311 scopus 로고    scopus 로고
    • Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumors
    • Fizazi K., Prow D.M., Do K.A., et al. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumors. Br J Cancer 2002, 86:1555-1560.
    • (2002) Br J Cancer , vol.86 , pp. 1555-1560
    • Fizazi, K.1    Prow, D.M.2    Do, K.A.3
  • 23
    • 1042303683 scopus 로고    scopus 로고
    • The management and survival of patients with advanced germ-cell tumors: Improving outcome in intermediate and poor prognosis patients
    • Bhala N., Coleman J.M., Radstone C.R., et al. The management and survival of patients with advanced germ-cell tumors: Improving outcome in intermediate and poor prognosis patients. Clin Oncol (R Coll Radiol) 2004, 16:40-47.
    • (2004) Clin Oncol (R Coll Radiol) , vol.16 , pp. 40-47
    • Bhala, N.1    Coleman, J.M.2    Radstone, C.R.3
  • 24
    • 34547608744 scopus 로고    scopus 로고
    • GAMEC-a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours
    • Shamash J., Powles T., Ansell W., et al. GAMEC-a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours. Br J Cancer 2007, 97:308-314.
    • (2007) Br J Cancer , vol.97 , pp. 308-314
    • Shamash, J.1    Powles, T.2    Ansell, W.3
  • 25
    • 0028339458 scopus 로고
    • Synergistic action of taxol with tiazofurin and methotrexate in human breast cancer cells: Schedule-dependence
    • Yeh Y.A., Olah E., Wendel J.J., et al. Synergistic action of taxol with tiazofurin and methotrexate in human breast cancer cells: Schedule-dependence. Life Sci 1994, 54:PL431-PL435.
    • (1994) Life Sci , vol.54
    • Yeh, Y.A.1    Olah, E.2    Wendel, J.J.3
  • 26
    • 0032240948 scopus 로고    scopus 로고
    • Schedule dependent synergism and antagonism between paclitaxel and methotrexate in human carcinoma cell lines
    • Kano Y., Akutsu M., Tsunoda S., et al. Schedule dependent synergism and antagonism between paclitaxel and methotrexate in human carcinoma cell lines. Oncol Res 1998, 10:347-354.
    • (1998) Oncol Res , vol.10 , pp. 347-354
    • Kano, Y.1    Akutsu, M.2    Tsunoda, S.3
  • 27
    • 0034120074 scopus 로고    scopus 로고
    • Comparative study of sequential combinations of paclitaxel and methotrexate on a human bladder cancer cell line
    • Cos J., Bellmunt J., Soler C., et al. Comparative study of sequential combinations of paclitaxel and methotrexate on a human bladder cancer cell line. Cancer Invest 2000, 18:429-435.
    • (2000) Cancer Invest , vol.18 , pp. 429-435
    • Cos, J.1    Bellmunt, J.2    Soler, C.3
  • 28
    • 0036052170 scopus 로고    scopus 로고
    • Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer
    • Bellmunt J., Cos J., Clèries R., et al. Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer. Cancer Invest 2002, 20:673-685.
    • (2002) Cancer Invest , vol.20 , pp. 673-685
    • Bellmunt, J.1    Cos, J.2    Clèries, R.3
  • 29
    • 0030069958 scopus 로고    scopus 로고
    • A phase I investigation of the sequential use of methotrexate and paclitaxel with and without G-CSF for the treatment of solid tumors
    • Huber M.H., Lee J.S., Newman R.A., et al. A phase I investigation of the sequential use of methotrexate and paclitaxel with and without G-CSF for the treatment of solid tumors. Ann Oncol 1996, 7:59-63.
    • (1996) Ann Oncol , vol.7 , pp. 59-63
    • Huber, M.H.1    Lee, J.S.2    Newman, R.A.3
  • 30
    • 78149369787 scopus 로고
    • World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment (WHO Offset Publication No. 48,). Geneva, Switzerland: World Health Organization
    • World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment (WHO Offset Publication No. 48, 1979). Geneva, Switzerland: World Health Organization.
    • (1979)
  • 31
    • 0032703762 scopus 로고    scopus 로고
    • First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis
    • Bokemeyer C., Kollmannsberger C., Meisner C., et al. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. J Clin Oncol 1999, 17:3450-3456.
    • (1999) J Clin Oncol , vol.17 , pp. 3450-3456
    • Bokemeyer, C.1    Kollmannsberger, C.2    Meisner, C.3
  • 32
    • 0031943997 scopus 로고    scopus 로고
    • Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: A Randomized Medical Research Council/European Organization for Research and Treatment of Cancer Study
    • Kaye S.B., Mead G.M., Fossa S., et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: A Randomized Medical Research Council/European Organization for Research and Treatment of Cancer Study. J Clin Oncol 1998, 16:692-701.
    • (1998) J Clin Oncol , vol.16 , pp. 692-701
    • Kaye, S.B.1    Mead, G.M.2    Fossa, S.3
  • 33
    • 0037364734 scopus 로고    scopus 로고
    • Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors
    • Christian J.A., Huddart R.A., Norman A., et al. Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors. J Clin Oncol 2003, 21:871-877.
    • (2003) J Clin Oncol , vol.21 , pp. 871-877
    • Christian, J.A.1    Huddart, R.A.2    Norman, A.3
  • 34
    • 0030839120 scopus 로고    scopus 로고
    • Treatment of men with metastatic non-seminomatous germ cell tumors with cyclical POMB/ACE chemotherapy
    • Bower M., Newlands E.S., Holden L., et al. Treatment of men with metastatic non-seminomatous germ cell tumors with cyclical POMB/ACE chemotherapy. Ann Oncol 1997, 8:477-483.
    • (1997) Ann Oncol , vol.8 , pp. 477-483
    • Bower, M.1    Newlands, E.S.2    Holden, L.3
  • 35
    • 0037505857 scopus 로고    scopus 로고
    • Paclitaxel, ifosfamide, and cisplatin regimen is feasible for Japanese patients with advanced germ cell cancer
    • Kawai K., Miyazaki J., Tsukamoto S., et al. Paclitaxel, ifosfamide, and cisplatin regimen is feasible for Japanese patients with advanced germ cell cancer. Jpn J Clin Oncol 2003, 33:127-131.
    • (2003) Jpn J Clin Oncol , vol.33 , pp. 127-131
    • Kawai, K.1    Miyazaki, J.2    Tsukamoto, S.3
  • 36
    • 0032735907 scopus 로고    scopus 로고
    • Management of intermediate-prognosis germ-cell cancer: Results of a phase I/II study of Taxol-BEP
    • de Wit R., Louwerens M., de Mulder P.H., et al. Management of intermediate-prognosis germ-cell cancer: Results of a phase I/II study of Taxol-BEP. Int J Cancer 1999, 83:831-833.
    • (1999) Int J Cancer , vol.83 , pp. 831-833
    • de Wit, R.1    Louwerens, M.2    de Mulder, P.H.3
  • 37
    • 38849124806 scopus 로고    scopus 로고
    • Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): Results of the sCR2 international study
    • Fizazi K., Oldenburg J., Dunant A., et al. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): Results of the sCR2 international study. Ann Oncol 2008, 19:259-264.
    • (2008) Ann Oncol , vol.19 , pp. 259-264
    • Fizazi, K.1    Oldenburg, J.2    Dunant, A.3
  • 38
    • 0025894985 scopus 로고
    • Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma
    • Harstrick A., Schmoll H.J., Wilke H., et al. Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma. J Clin Oncol 1991, 9:1549-1555.
    • (1991) J Clin Oncol , vol.9 , pp. 1549-1555
    • Harstrick, A.1    Schmoll, H.J.2    Wilke, H.3
  • 39
    • 0344734200 scopus 로고    scopus 로고
    • Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor
    • Loehrer P.J., Gonin R., Nichols C.R., et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 1998, 16:2500-2504.
    • (1998) J Clin Oncol , vol.16 , pp. 2500-2504
    • Loehrer, P.J.1    Gonin, R.2    Nichols, C.R.3
  • 40
    • 0031943040 scopus 로고    scopus 로고
    • Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom
    • Fosså S.D., Kaye S.B., Mead G.M., et al. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 1998, 16:716-724.
    • (1998) J Clin Oncol , vol.16 , pp. 716-724
    • Fosså, S.D.1    Kaye, S.B.2    Mead, G.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.